By Associate Professor Anthony Michael Joshua

Conference Abstracts

Chen J; Joshua AM; Denmeade SR; Antonarakis ES; Crumbaker M, 2019, 'High dose testosterone in men with metastatic castrate-resistant prostate cancer (mCRPC) and homologous recombination deficiency (HRD).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, Vol. 37, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2019 - 04 June 2019, http://dx.doi.org/10.1200/JCO.2019.37.15_suppl.TPS5095

Jiang DM; Fallah-Rad N; Lee R; Ng P; Smith AD; Hansen AR; Joshua AM; Sridhar SS, 2019, 'Minimizing drug wastage (DW) and cost of cabazitaxel used to treat metastatic castrate-resistant prostate cancer (mCRPC).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, Vol. 37, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2019 - 04 June 2019, http://dx.doi.org/10.1200/JCO.2019.37.15_suppl.6550

Thavaneswaran S; Ballinger ML; Grady J; Cowley M; Joshua A; Sebastian L; Collignon E; Silvestri A; Kansara M; Pinese M; Sjoquist KM; Hague W; Lee CK; Simes J; Thomas DM, 2019, 'The Cancer Molecular Screening and Therapeutics Program (MoST): Actionable mutation frequencies in a population with rare and less common cancers.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, Vol. 37, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2019 - 04 June 2019, http://dx.doi.org/10.1200/JCO.2019.37.15_suppl.3136

Alibhai SMH; Breunis H; Gregg RW; Hansen AR; Warde PR; Timilshina N; Tomlinson G; Joshua AM; Fleshner NE; Emmenegger U, 2019, 'Validating the Cancer and Aging Research Group (CARG) toxicity prediction tool in older men receiving chemotherapy for metastatic castration-resistant prostate cancer (mCRPC) and extending it to androgen receptor targeted agents.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, Vol. 37, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2019 - 04 June 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000487345804179&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Emmett L; Chalasani V; Kneebone A; Hruby G; Joshua AM, 2019, 'Rapid modulation of PSMA expression by ADT: Serial PSMA PET in men commencing androgen blockade.', in RADIOTHERAPY AND ONCOLOGY, ELSEVIER IRELAND LTD, ITALY, Milan, Vol. 133, pp. S445 - S446, presented at 38th Annual Meeting of the European-Society-for-Radiotherapy-and-Oncology (ESTRO), ITALY, Milan, 26 April 2019 - 30 April 2019, http://dx.doi.org/10.1016/S0167-8140(19)31267-8

Rose AAN; Armstrong SM; Hogg D; Butler M; Joshua AM; Ghazarian D; Kamel-Reid S; Al Habeeb A; Chappell MA; Ross K; Amir E; Bedard PL; Siu L; Spreafico A, 2019, 'The relationship between BRAF/NRAS/KIT genomic driver mutations and anti-PD1 immunotherapy responses in patients with advanced melanoma', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, GA, Atlanta, Vol. 79, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), GA, Atlanta, 29 March 2019 - 03 April 2019, http://dx.doi.org/10.1158/1538-7445.AM2019-3141

Millward M; Gan HK; Joshua AM; Kuo JC-Y; Prawira A; Richardson GE; Barbee SD; Inamdar SP; Pierce KL; Qureshi M; Horvath L, 2019, 'FPT155-001: A phase Ia/Ib study of FPT155 (CD80-FC) in patients with advanced solid tumors.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, CA, San Francisco, Vol. 37, presented at ASCO-SITC Clinical Immuno-Oncology Symposium, CA, San Francisco, 28 February 2019 - 02 March 2019, http://dx.doi.org/10.1200/JCO.2019.37.8_suppl.TPS42

Massard C; Retz M; Hammerer P; Quevedo F; Fong PCC; Berry WR; Gurney H; Piulats JM; Joshua A; Linch MD; Kolinsky M; Romano E; Sridhar SS; Conter HJ; Augustin M; Wu H; Schloss C; Poehlein CH; Yu EY, 2019, 'Keynote-365 cohort b: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, CA, San Francisco, Vol. 37, presented at ASCO-SITC Clinical Immuno-Oncology Symposium, CA, San Francisco, 28 February 2019 - 02 March 2019, http://dx.doi.org/10.1200/JCO.2019.37.7_suppl.170

Fong PCC; Retz M; Drakaki A; Massard C; Berry WR; Romano E; De Bono JS; Feyerabend S; Appleman LJ; Conter HJ; Sridhar SS; Shore ND; Linch MD; Joshua A; Gurney H; Wu H; Schloss C; Poehlein CH; Yu EY, 2019, 'Keynote-365 cohort C: Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, CA, San Francisco, Vol. 37, presented at ASCO-SITC Clinical Immuno-Oncology Symposium, CA, San Francisco, 28 February 2019 - 02 March 2019, http://dx.doi.org/10.1200/JCO.2019.37.7_suppl.171

Mak B; Mahon KL; Stockler MR; Joshua AM; Zhang AY; Parnis F; Meikle P; Horvath L, 2019, 'Modulation of plasma lipidomic signature in metastatic castration-resistant prostate cancer (mCRPC).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, CA, San Francisco, Vol. 37, presented at ASCO-SITC Clinical Immuno-Oncology Symposium, CA, San Francisco, 28 February 2019 - 02 March 2019, http://dx.doi.org/10.1200/JCO.2019.37.7_suppl.TPS331

Herrera-Caceres JO; Goldberg H; Hansen AR; Sridhar SS; Hamilton RJ; Finelli A; Zlotta A; Joshua AM; Fleshner NE, 2019, 'Preoperative trial of neoadjuvant abiraterone plus or minus cabazitaxel: Early results.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, CA, San Francisco, Vol. 37, presented at ASCO-SITC Clinical Immuno-Oncology Symposium, CA, San Francisco, 28 February 2019 - 02 March 2019, http://dx.doi.org/10.1200/JCO.2019.37.7_suppl.98

Thavaneswaran S; Sebastian L; Ballinger M; Cowley M; Grady J; Joshua A; Lee C; Sjoquist K; Hague W; Simes J; Thomas D, 2018, 'The cancer molecular screening and therapeutics program (MoST): A molecular screening platform with multiple, parallel, signal-seeking therapeutic substudies', in Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii147, http://dx.doi.org/10.1093/annonc/mdy279.434

Kanjanapan Y; Day D; Wang L; Hansen AR; Razak ARA; Spreafico A; Leighl NB; Joshua AM; Butler MO; Hogg D; Siu LL; Bedard PL, 2018, 'Hyperprogressive disease (HPD) in early-phase immunotherapy (IO) trials.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, Vol. 36, http://dx.doi.org/10.1200/JCO.2018.36.15_suppl.3063

Kanjanapan Y; Day D; Butler M; Wang L; Joshua AM; Hogg D; Leighl NB; Razak ARA; Hansen AR; Boujos S; Chappell MA; Chow K; Paolo M; Sherwin B; Stayner L-A; Soultani L; Zambrana A; Siu LL; Bedard PL; Spreafico A, 2017, 'Immune related adverse events (irAEs) in early phase immunotherapy (IO) trials: Implications for recommended phase 2 dose (RP2D) determination', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, SPAIN, Madrid, Vol. 28, presented at 42nd European-Society-for-Medical-Oncology Congress (ESMO), SPAIN, Madrid, 08 September 2017 - 12 September 2017, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000411324001056&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Khoja L; Atenafu E; Joshua AM, 2017, 'Validating prognostic models in metastatic uveal melanoma (MUM), an international rare cancers initiative', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, SPAIN, Madrid, Vol. 28, presented at 42nd European-Society-for-Medical-Oncology Congress (ESMO), SPAIN, Madrid, 08 September 2017 - 12 September 2017, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000411324003103&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Lin FP-Y; Martin C; Kocbek S; Joshua AM; Dear RF-G; Lim E; Chantrill LA; Chin VT; Epstein RJ, 2017, 'Identifying determinants of quality of life in patients undergoing systemic therapy for solid tumors.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, Vol. 35, presented at 53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET, IL, Chicago, 02 June 2017 - 07 June 2017, http://dx.doi.org/10.1200/JCO.2017.35.15_suppl.6596

Buckman RA; Berman HK; Sridhar SS; Joshua AM, 2010, 'How much do the side effects of chemotherapy matter? Patients' attitudes to side effects versus a potential loss of duration of remission', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, Vol. 28, http://dx.doi.org/10.1200/jco.2010.28.15_suppl.e19585

Back to profile page